Boehringer Says Survodutide Cuts Liver Fat 63.1% as 16.6% Weight Loss Faces GLP-1 Rivals
Updated
Updated · Reuters · Jun 7
Boehringer Says Survodutide Cuts Liver Fat 63.1% as 16.6% Weight Loss Faces GLP-1 Rivals
3 articles · Updated · Reuters · Jun 7
Summary
MRI data from a 76-week late-stage obesity trial showed survodutide cut visceral fat by up to 34% and liver fat by up to 63.1%, while lean mass made up no more than 10.8% of body-composition change at the top 6-mg dose.
Those findings strengthen Boehringer Ingelheim's pitch that the injectable can compete on where weight is lost, not just on headline weight-loss figures, after April data showed average loss of 16.6%.
In a separate late-stage MASLD study, up to 84.2% of overweight or obese patients on survodutide achieved at least 30% liver-fat reduction after 48 weeks, versus 24.3% on placebo; 61% reached liver-fat normalization versus 5.7%.
The drug, licensed from Zealand Pharma, enters a crowded obesity field where analysts say benefits such as lean-mass preservation, liver-disease impact, tolerability and treatment persistence could determine commercial success.
Could a new obesity drug also be the key to reversing widespread chronic liver disease?
How does this drug trick the body into burning harmful fat while preserving essential muscle?
Survodutide Delivers 16.6% Weight Loss and Major Liver Benefits: Phase III Data from ADA 2026
Overview
The ADA 2026 Scientific Sessions highlighted the groundbreaking Phase III results for survodutide, a dual agonist therapy that could transform obesity and liver disease treatment. Data from the SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials showed that survodutide led to significant weight loss—up to 16.6%—and impressive reductions in liver fat. Earlier studies also reported weight reductions of up to 19% over 46 weeks. These results underscore survodutide’s strong potential to set new standards in managing obesity and metabolic liver disease, offering hope for improved outcomes in patients facing these serious health challenges.